Impaired induction of DNA lesions during immunoglobulin class-switch recombination in humans influences end-joining repair

Sven Kracker^{a,b}, Kohsuke Imai^{c,1}, Pauline Gardès^{a,b,1}, Hans D. Ochs^d, Alain Fischer^{a,b,e}, and Anne H. Durandy^{a,b,e,2}

^aInstitut National de la Santé et de la Recherche Médicale U768, Hôpital Necker Enfants Malades, 75015 Paris, France; ^bFaculté de Médecine, Université Paris Descartes, 75006 Paris, France; ^cDepartment of Pediatrics, National Defense Medical College, Saitama 359-8513, Japan; ^dDepartment of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA 98101; and ^eUnité d'Immunologie et Hématologie Pédiatrique, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants Malades, 75015 Paris, France

Edited by Frederick W. Alt, Howard Hughes Medical Institute, Harvard Medical School, The Children's Hospital, Immune Disease Institute, Boston, MA, and approved November 9, 2010 (received for review August 24, 2010)

Ig class-switch recombination (CSR) is a region-specific process that exchanges the constant Ig heavy-chain region and thus modifies an antibody's effector function. DNA lesions in switch (S) regions are induced by activation-induced cytidine deaminase (AID) and uracil-DNA glycosylase 2 (UNG2), subsequently processed to DNA breaks, and resolved by either the classical nonhomologous endjoining pathway or the alternative end-joining pathway (XRCC4/ DNA ligase 4- and/or Ku70/Ku80-independent and prone to increased microhomology usage). We examined whether the induction of DNA lesions influences DNA end-joining during CSR by analyzing S_{μ} -S α recombination junctions in various human lg CSR defects of DNA lesion induction. We observed a progressive trend toward the usage of microhomology in Sµ–S α recombination junctions from AID-heterozygous to AID-autosomal dominant to UNG2-deficient B lymphocytes. We thus hypothesize that impaired induction of DNA lesions in S regions during CSR leads to unusual end-processing of the DNA breaks, resulting in microhomology-mediated end-joining, which could be an indication for preferential processing by alternative end-joining rather than by classical nonhomologous end-joining.

antibody maturation | switch junction | DNA repair

uring immune responses, mature B cells diversify their Ig D genes through class-switch recombination (CSR) and somatic hypermutation (SHM). The latter mechanism introduces nontemplated point mutations in the variable region of Ig genes and thereby enables the selection of antibodies with increased affinity for the antigen. CSR modulates antibody effector function by replacing one constant region with another in a deletionmediated recombination process, while retaining the binding specificity (variable region) of the B-cell receptor. Both processes are initiated by the enzyme activation-induced cytidine deaminase (AID), which deaminates cytosine to produce U:G mismatches in target DNA (1-3). GC-rich regions, so-called "switch" (S) regions, present in front of each constant region and of varying lengths, are the target DNAs for AID during CSR. The main route for processing AID-induced lesions involves uracil excision through several pathways, primarily the pathway involving uracil-DNA glycosylase (UNG2) (4, 5). Abasic sites are further processed to generate DNA double-strand breaks (DSBs), which are obligate intermediates in CSR (6, 7). The DSBs activate damage response proteins, such as PI3-like protein kinase ataxia-telangiectasia mutated, the phosphorylated histone variant H2AX, the MRN complex (MRE11, RAD50, and NBS1), MDC1, and 53BP1, all of which are known to play roles in CSR in promoting appropriate repair and efficient long-range, region-specific recombination (8-14). In CSR, the resolution step is normally mediated by the classical nonhomologous end-joining pathway (c-NHEJ); however, recent reports strongly suggest that resolution also can be mediated (albeit at a lower frequency) by Ku 70-, Ku 80-, and/or

XRCC4/DNA ligase 4-independent alternative end-joining (AEJ) pathways, which are biased toward microhomology usage, and which components are not yet well defined (15–18). The low frequency of microhomologies in S junctions from healthy individuals suggests that under normal conditions, AEJ is inefficient or even excluded from the CSR process, raising the question of how the choice between these pathways is made.

In the other lymphocyte-specific antigen receptor gene diversification process [V(D)J recombination], DNA breaks are induced by the recombinase-activating gene 1/2 (RAG1/2) in a site-specific manner. RAG1/2 core or RAG2 truncated protein (with a frameshift mutation at aa 361) enables V(D)J recombination in the absence of components of the c-NHEJ pathway, providing evidence for (*i*) the existence of an AEJ pathway and (*ii*) a role for WT RAG1/2 in recruiting c-NHEJ for repair and/or excluding AEJ components (19). This observation suggests that AEJ is excluded from the V(D)J process by the time that DNA lesions are induced.

AID and UNG can be viewed as the CSR "counterparts" of RAG1/2, given that they are responsible for inducing DNA lesions in the S regions. AID activity is essential for CSR, and the expression level of this enzyme influences the efficiency of the process. Haploinsufficiency has been reported for AID-deficient mice, although no evidence for this has been reported in humans on the basis of serum Ig levels and in vitro CSR experiments (20-22). Conversely, overexpression of AID in the CH12 murine B lymphoma cell line and in murine B lymphocytes increases the frequency of cells undergoing CSR (3, 23). We have found evidence of defective CSR in patients bearing a heterozygous deletion in which the C-terminal part of AID, including the nuclear export signal, is missing, resulting in an autosomal dominant form of AID (due to a dominant-negative effect) (20). AID^{+/C-term} mutants, together with the UNG2-deficient setting that we described previously (4), provide a unique opportunity to study DSB repair pathways in human CSR with impaired AID activity or in the absence of UNG. Using a PCR-based assay, we established that the nature of Sµ-Sα CSR junctions differs in AID-heterozygous (AID^{+/-}), AID-autosomal dominant, and UNG2-deficient B cells compared with controls, with a progressive, marked shift toward the use of microhomologies (≥ 10 bp), indicating unusual processing of altered DNA lesions during CSR.

Author contributions: S.K., A.F., and A.H.D. designed research; S.K., K.I., and P.G. performed research; K.I., H.D.O., and A.H.D. contributed new reagents/analytic tools; S.K., A.F., and A.H.D. analyzed data; and S.K., A.F., and A.H.D. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

¹K.I. and P.G. contributed equally to this work.

²To whom correspondence should be addressed. E-mail: anne.durandy@inserm.fr.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1012591108/-/DCSupplemental.

Results

Sµ-Sα Junctions Exhibit Trends Toward Microhomology in AID-Heterozygous, AID-Autosomal Dominant, and UNG2-Deficient B Cells. To study the impact of DNA lesion induction on DSB repair during CSR, we purified genomic DNA from peripheral blood from healthy donors (controls), $AID^{+/-}$ patients, $AID^{+/C-term\Delta}$ patients carrying the previously described R190X mutation (20) or the recently identified V186X mutation, and the UNG-deficient (UNG2^{-/-}) patients described earlier. The various mutations analyzed are listed in Materials and Methods. Both AID^{+/C-termΔ} mutations resulted in a dominant-negative form of AID. Individual Sµ–S α fragments from the various patients were amplified using a nested PCR assay, as described previously (24). The amplification efficiency of $S\mu$ -S α fragments was similar for the AID^{+/-}, AID^{+/C-term Δ}, and control samples, in contrast to the UNG2^{-/-} samples, in which fewer bands were amplified by nested PCR. In particular, only a few S μ -S α fragments were amplified in UNG2^{-/-} patient P1 (as identified in ref. 4) (Fig. S1). To define the S junctions, the amplified S μ -S α fragments were sequenced and aligned with the germline S μ and S α sequences. In all, we characterized 67 Sµ-Sa recombination junctions in blood samples from five AID^{+/-} patients, 84 from five AID^{+/C-term Δ} patients, and 88 from three UNG2^{-/-} patients. The distribution of Sµ–S α junctions for each individual patient is shown in Fig. S2. Of note, α 1 junctions were more prevalent than α^2 junctions in controls (83%) compared with AID^{+/-}, AID^{+/C-termA}, and UNG2^{-/-} patients (AID^{+/-}, 66%, P < 0.05, χ^2 test; AID^{+/C-termA}, 58%, P < 0.001; UNG2^{-/-}, 53%, P < 0.0001). Because the S α 2 sequence does not exhibit enhanced microhomology with Sµ compared with the S α 1 sequence, our observation might be related to increased IgA2 production in the patients, based on recurrent bacterial intestinal stimulation (25, 26).

There was a trend toward an increased overlap between the Sµ and S α sequences in recombination junctions derived from AID^{+/-} cells (6.7 \pm 0.8 nucleotides vs. 4.5 \pm 0.6 in controls; P < 0.05, Student t test) (Fig. 1). A more pronounced increase in overlap between the S μ and S α sequences was observed with recombination junctions derived from AID^{+/C-term Δ} and UNG2^{-/-} patients (8.9 ± 0.8 and 9.8 \pm 0.8 nucleotides, respectively) compared with controls (P < 0.0001) (Fig. 1). The increase in microhomology between Sµ and Sα sequences in recombination junctions from AID^{+/-}, AID^{+/C-term Δ}, and UNG2^{-/-} patients was associated with (*i*) a significant decrease in the proportion of Sµ-Sa junctions with no microhomology (6% in both AID groups and 2% in UNG2^{-/-} patients vs. 17% in controls; P < 0.05 and < 0.01, respectively, χ^2 test) (Fig. 2A) and (ii) a significantly greater proportion of junctions exhibiting a long microhomology (≥ 10 bp) for the AID^{+/C-term Δ} and UNG2^{-/-} patients (36% and 43%, respectively, vs. 10% in controls; P < 0.001, χ^2 test; AID^{+/-}, 19%, P < 0.09) (Fig. 24). We excluded the possibility that the increased microhomology observed in the junctions from the patients was the consequence of enhanced Sa2 usage, because when analyzed separately, Sµ-Sa1 and Sµ-Sa2 from AID^{+/-}, AID^{+/C-term Δ}, and UNG2^{-/-} patients demonstrated the same preferential microhomology usage (Fig. 2 B and C).

A recent study of Sµ–S α junctions recommended the use of aged-matched controls, given that S junctions from young subjects are biased toward microhomology (27). In an aged-matched analysis, we confirmed the trend toward microhomology in separately studied adult and young AID^{+/C-term Δ} and UNG2^{-/-} patients and adult AID^{+/-} patients; young AID^{+/-} patients were not available (Fig. 3).

Together, our results indicate end-processing biased toward long microhomologies in UNG2^{-/-}, AID^{+/C-term Δ}, and, to a lesser extent, AID^{+/-} B cells.



Fig. 1. Distribution of microhomology lengths for $S\mu$ - $S\alpha$ recombination junctions from AID^{+/-}, AID^{+/-} term^Δ, and UNG2^{-/-} patients. Each symbol indicates a unique $S\mu$ - $S\alpha$ junction. The average length for each group and *P* values (two-tailed unpaired Student *t* test) are indicated. Junctions with insertions were excluded from this representation. The figure represents 72 control, 54 AID^{+/-}, 68 AID^{+/-} cterm^Δ, and 72 UNG2^{-/-} Sµ-S\alpha junctions. The Sµ-S\alpha junctions obtained from the same patient in each group are marked with the same symbol. Open circles and open triangles indicate Sµ-S\alpha junctions from children.

Position of Sµ and Sα Breakpoints in Switch Junctions from AlD-Heterozygous, AlD-Autosomal Dominant, and UNG2-Deficient B Cells. We next analyzed whether the end-processing biased toward microhomologies in UNG2^{-/-}, AID^{+/C-termΔ}, and AID^{+/-} cells also affects the position of the Sµ and Sα breakpoints. In DNA ligase 4–deficient B cells, significantly more Sµ breakpoints were located in the stretch of the Sµ region (position 275–760) that has the greatest homology with Sα1 and Sα2 (17). We observed this phenomenon for Sµ breakpoints in UNG2^{-/-} and AID^{+/C-termΔ} patients (82% and 75%, respectively, of all Sµ breakpoints vs. 54% in controls; *P* < 0.0001 and < 0.01, respectively, χ^2 test), indicating the need for donor/acceptor homology in DSB resolution, but not in AID^{+/-} patients (63%) (Fig. 4). We conclude that the recombination of Sµ with Sα regions in UNG2^{-/-} and AID^{+/C-termΔ} cells depends in part on the presence of microhomologous sequences.

Mutations in S_µ-S_{α} Junctions from AID-Heterozygous, AID-Autosomal Dominant, and UNG2-Deficient B Cells. Point mutations occurring close to the recombination junction are supposedly generated during the resolving step of CSR, given that they are generally more frequent and mostly affect GC residues, in comparison with point mutations in the germline Sµ region, which exhibit a pattern similar to SHM in V regions and thus likely involve a different mechanism (28, 29). A lower number of mutations around the Sµ–S α junctions (±15 bp) has been reported in patients with Artemis deficiency and Ataxia-telangiectasia compared with controls, suggesting that DNA ends are not normally processed in these individuals (27). We examined the Sµ–S α junctions from the UNG2^{-/-}, AID^{+/C-term Δ}, and AID^{+/-} cells for mutations and found significantly fewer mutations located close to the junctions in the $UNG2^{-/-}$ and $AID^{+/C-term\Delta}$ patients compared with controls (4.5% and 7.9%, respectively, vs. 14.2%; P < 0.01 and < 0.05, respectively, χ^2 test), but not in the AID^{+/-} patients (10.4%) (Table 1). We also noted a significant shift to-



Fig. 2. Characterization of Sμ-Sα recombination junctions. The bar graphs show perfectly matched microhomology at junctions of PCR products cloned from the indicated B cells. White bars indicate sequences from control cells, light-gray bars indicate sequences from AID^{+/-} cells, dark-gray bars indicate sequences from AID^{+/-} cells, and black bars indicate sequences from UNG2^{-/-} cells. Statistical analyses were performed with the χ^2 test. Statistically significant differences from control cells are shown. *P < 0.05; **P < 0.01; ***P < 0.001. (A) Characterization of $S\mu$ -S α recombination junctions for microhomology. Data are based on 103 junctions from controls, 67 junctions from $AID^{+/-}$ patients, 84 junctions from $AID^{+/C-term\Delta}$ patients, and 88 junctions from UNG2^{-/-} patients. (B) Analysis of $S\mu$ -S α 1 recombination junctions. Shown are bar graphs based on 85 junctions from controls, 44 junctions from AID^{+/-} patients, 49 junctions from AID^{+/C-term} patients, and 35 junctions from UNG2-/- patients from the pool of junctions shown in A. (C) Bar graphs for $S\mu$ -S α 2 recombination junctions based on 18 junctions from controls, 23 junctions from AID+/patients, 35 junctions from AID^{+/C-term} patients, and 53 junctions from UNG2^{-/-} patients from the pool of junctions shown in A.

ward AT mutations in the AID^{+/C-termΔ} patients (AT vs. GC; 45% in AID^{+/C-termΔ} patients vs. 14% in controls; P < 0.01, χ^2 test) (Table 1), possibly indicating a different resolution of Sµ–Sα junctions than in controls.

We found no differences between AID^{+/-} patients and controls in terms of mutations in the Sµ core region, excluding mutations close to (i.e., within 15 bp) the S junction (Table 1). In contrast, the frequency of mutations in the Sµ core region was significantly lower in UNG2^{-/-} and AID^{+/C-termΔ} patients compared with controls (4.9% and 4.8%, respectively, vs. 6.6%; P <0.05 for both groups, χ^2 test) and indicated a shift toward AT mutations in the AID^{+/C-termΔ} group (Table 1). This might indicate an increased number of lesions on which Poln was active (30). However, the significantly higher proportion of GC transitions observed in the rearranged UNG2^{-/-} Sµ core region sequences (95% vs. 55% in controls; P < 0.001, χ^2 test) (Table 1) was reminiscent of the UNG-deficient SHM pattern (4). In conclusion, the analysis of mutations in Sµ–S α junctions derived from UNG2^{-/-} and AID^{+/C-term Δ} B cells is in agreement with an unusual end-processing.

Discussion

Our analysis of Sµ–S α junctions in AID^{+/-}, AID^{+/C-term Δ}, and UNG2^{-/-} patients provides evidence to suggest that the choice



Fig. 3. Age-dependent characterization of $S\mu$ - $S\alpha$ junctions. The bar graphs show perfectly matched microhomology at junctions of PCR products cloned from B cells. White bars indicate sequences from control cells, light-gray bars indicate sequences from AID^{+/-} cells, dark-gray bars indicate sequences from $AID^{+/-}$ cells, and black bars indicate sequences from $UNG2^{-/-}$ cells. Statistical analyses were performed with the χ^2 test. Statistical significant differences are shown. *P < 0.05; **P < 0.01; **P < 0.01. (A) Characterization of $S\mu$ - $S\alpha$ recombination junctions for microhomology derived from adult patients. Data are based on 70 junctions from controls, 67 junctions from $AID^{+/-}$ adult patients, 52 junctions from $AID^{+/-}$ adult patients, and 56 junctions from $UNG2^{-/-}$ adult patients from the pool of junctions from $ING2^{-/-}$ patients, $S\mu$ - $S\alpha$ recombination junctions from children (age 4–14 y). Shown are bar graphs based on 33 junctions from controls, 32 junctions from $AID^{+//-}$ patients, and 32 junctions from $UNG2^{-/-}$ patients from the pool of junctions shown in Fig. 2A. No $AID^{+//-}$ term^Δ patients, and 32 junctions from $UNG2^{-/-}$ patients from the pool of junctions shown in Fig. 2A. No $AID^{+//-}$ term^Δ patients from $UNG2^{-/-}$ patients from the pool of junctions shown in Fig. 2A. No $AID^{+//-}$ term^Δ patients from $UNG2^{-/-}$ patients from the pool of junctions shown in Fig. 2A. No $AID^{+//-}$ term^Δ patients from $UNG2^{-/-}$ patients from the pool of junctions shown in Fig. 2A. No $AID^{+//-}$ term^Δ patients from $UNG2^{-/-}$ patients from the pool of junctions shown in Fig. 2A. No $AID^{+//-}$ term^Δ patients from $UNG2^{-/-}$ patients from the pool of junctions shown in Fig. 2A. No $AID^{+//-}$ term^Δ patients from $UNG2^{-/-}$ patients from the pool of junctions shown in Fig. 2A. No $AID^{+/-}$ term^Δ patients from $UNG2^{-/-}$ patients from the pool of junctions shown in Fig. 2A. No $AID^{+/-}$ term^Δ patients from $UNG2^{-/-}$ patie

of the DNA repair pathway for S region end-joining is made at the start of the CSR process (i.e., as soon as DNA lesions have been induced). We chose to analyze $S\mu$ -S α junctions because these junctions are known to be strongly affected by deficiencies in DNA ligase 4 or PMS2, in contrast to $S\mu$ -S γ junctions, which are little influenced by these deficiencies (17, 31). We also attempted to amplify $S\mu$ -S α junctions from homozygous AIDdeficient (AID^{-/-}) patients but failed, most likely due to the complete absence of CSR in these patients (1).

We analyzed the frequency of mutations in the Sµ core region from recombined S regions and found that it was significantly lower in UNG2^{-/-} and AID^{+/C-termΔ} patients compared with controls. Contradictory data have been reported in mice, with retroviral overexpression of the AID^{+/C-termΔ} (Δ 189–198) murine mutant in AID^{-/-} B cells showing normal in vitro cytidine deaminase activity and induction of mutations in the Sµ region, but leading to inefficient CSR (32). This discrepancy could be related to the sequencing of different regions in Sµ, or to the fact that the murine study analyzed mutations in germline (i.e., unrearranged) Sµ regions from B cells undergoing in vitro CSR, whereas we analyzed rearranged Sµ regions from AID^{+/C-termΔ} patients that were successfully switched in vivo. A recent study suggested that AID participates via its C-terminal part in a multimolecular complex (supposedly at nuclear pores) necessary

22228 | www.pnas.org/cgi/doi/10.1073/pnas.1012591108

for its stability and CSR (33). Thus, the lower frequency in the Sµ core region from Sµ–Sα junctions derived from UNG2^{-/-} and AID^{+/C-termΔ} B cells could be explained by differences in the DNA repair/recombination environment.

The significantly lower frequency of mutations close to the junctions in UNG2^{-/-} and AID^{+/C-termΔ} patients compared with controls most likely reflects a different recombination and/or end-processing during CSR in these cells. The significantly higher AT: GC ratio of mutations in the AID^{+/C-termΔ} group must be interpreted with caution. Indeed, the overall number of mutations was low, and mutations close to the junctions might be corrupted by mutations introduced into Sµ before recombination. The difference in the frequency of mutations, as well as the progressive trend toward microhomology usage observed in AID^{+/C-termΔ}, AID^{+/C-termΔ}, and UNG2^{-/-} patients, correlated well with the in vivo CSR deficiency based on IgG and IgA serum levels, with AID^{+/-} normal, AID^{+/C-termΔ} decreased, and UNG2^{-/-} dramatically decreased or even absent (4, 20).

Several hypotheses, not exclusive, can be raised to explain why microhomology-mediated end-joining/recombination is favored in $AID^{+/-}$, $AID^{+/C-term\Delta}$, and $UNG2^{-/-}$ B cells. Induction of DNA lesions is likely impaired in cases of reduced AID activity or in the absence of UNG. Although DSBs are detectable in B cells with $AID^{+/C-term\Delta}$ mutations, they are undetectable in UNG-



Fig. 4. Scatterplot analysis of $S\mu$ and $S\alpha$ breakpoints. The *x*-axis and *y*-axis indicate the position of the $S\mu$ and $S\alpha$ breakpoints, respectively, with respect to the annotated S sequences. The vertical line indicates the start of the $S\mu$ region displaying the highest degree of homology with $S\alpha$ 1 and $S\alpha$ 2. For clarity, only the S μ breakpoints upstream of position 700 are shown. One AID^{+/-} switch-fragment and three AID^{+/C-term\Delta}, seven UNG2^{-/-}, and five control switch fragments were located in the more 3' part of $S\mu$ (i.e., downstream of position 800) and are thus not shown.

deficient B cells (4, 20). Fewer AID- and/or UNG-induced DNA lesions likely leads to staggered and long single-stranded DNA breaks that may require extensive processing by polymerases, such as polymerase μ or ζ (34, 35). Polymerase-mediated repair might lead to the insertion of nucleotides at the junctions due to template-independent synthesis, or to microhomologies due to fillin synthesis (34, 36). The polymerase-mediated repair is likely associated with the components of c-NHEJ (34); however, the microhomology length of >10 nucleotides and the location of the Sµ breakpoints observed in the analyzed patients argues for another pathway involving DNA end-resection to search for donor/acceptor homology. DNA end-resection facilitates microhomology-mediated end-joining/recombination and has been recently associated with AEJ (37). Fewer AID- and/or UNG-induced DNA lesions also could result in the absence of abasic sites located close to the DSB, which could favor AEJ processing, as suggested by a recent report demonstrating that abasic sites close to DSBs can be processed by Ku70's lyase activity and exclude AEJ (38).

Microhomology-mediated end-joining also could be the result of impaired recruitment of cofactor(s) involved in the processing/recombination of AID-induced lesions. Several studies have strongly suggested that the C-terminal part of AID could recruit a repair cofactor or target AID to specific areas, such as nuclear pores, thereby providing a special DNA repair/recombination environment (32, 33, 39). The detection of DSBs in the Sµ region from AID^{+/C-termΔ} B cells supports the impaired recruitment hypothesis for the AID^{+/C-termΔ} group. Other data suggest that UNG acts in CSR not only through its enzymatic activity, but also as an important docking protein (40). Interestingly, AID, UNG, and PMS2 involved in the generation of DNA lesions or breaks seem to exert further activity during S region end-joining. Why microhomology-mediated repair occurs in PMS2-deficient cells remains unclear (31, 41). A recent study with PMS2 endonuclease-deficient mice indicated that the presence of the PMS2 protein, but not its endonuclease activity, was required for proper S region end-joining, but that PMS2 endonuclease activity was still necessary for efficient CSR (42). These results suggest that an as-yet unknown interaction of PMS2 with a putative partner could recruit the c-NHEJ pathway and/or counteract microhomology-mediated repair. Thus, AID, UNG, and PMS2 could be involved in cofactor recruitment to facilitate c-NHEJ, a hypothesis reminiscent of the known complex role of RAG1/2 in V(D)J recombination (19). The nature of the cofactor(s) required for proper end-joining during CSR remains unknown; 53BP1 is a possible candidate, given the recent demonstration of its involvement in the decision between AEJ and c-NHEJ during the CSR process (37).

Whether the microhomology-mediated end-joining that we observed in AID^{+/-}, AID^{+/C-termΔ}, and UNG2^{-/-} cells is the actual result of AEJ (Ku70/Ku80- and/or XRCC4/DNA ligase 4– independent) or the consequence of modified c-NHEJ remains unresolved. The extent to which AEJ reflects a distinct bona fide repair mechanism or a compensatory pathway when c-NHEJ is defective is unclear (16, 36, 43).

In conclusion, the present study strongly suggests a direct link between DNA lesion induction in S regions during CSR and

	AT vs. GC	GC transition (G \rightarrow A; C \rightarrow T)	Total number of mutations	Number of bp sequenced	Frequency per 1,000 bp
Close to the jun	ction (± 15 bp)				
Controls	6 vs. 38 (14% vs. 86%)	22 (58%)	44	3,090	14.2
AID ^{+/-}	6 vs. 15 (29% vs. 71%)	10 (67%)	21	2,010	10.4
AID ^{+/C-term∆}	9 vs. 11 (45% vs. 55%)**	9 (82%)	20	2,520	7.9*
UNG2 ^{-/-}	2 vs. 10 (17% vs. 83%)	8 (80%)	12	2,640	4.5**
Within the S μ co	ore (>15 bp upstream of the junction))			
Controls	35 vs. 73 (32% vs. 68%)	40 (55%)	108	16,442	6.6
AID ^{+/-}	33 vs. 38 (46% vs. 53%)	26 (68%)	72	11,316	6.4
AID ^{+/C-term∆}	44 vs. 36 (55% vs. 45%)**	25 (69%)	80	16,650	4.8*
UNG2 ^{-/-}	34 vs. 55 (38% vs. 62%)	52 (95%)***	99	20,313	4.9*

Table 1. Mutations in $S\mu$ -S α fragments

Statistical analyses were performed using the χ^2 test. Statistically significant differences are shown in bold (*P < 0.05; **P < 0.01; ***P < 0.001). The Sµ core was defined as the 300-bp region starting from position Sµ 142 (X54713).

the DNA repair machinery subsequently involved in the endjoining process.

Materials and Methods

Patients. The study included the three UNG patients described previously (4), five AID-heterozygous adults (with a G203A, C441A, or C70T mutation or deletion of the entire coding region) from four independent families, three AID-autosomal dominant patients (with the previously described heterozy-gous R190X mutation) from two unrelated families [including patients 2-I-1 and 2-II-2 from a previous study (20)], and two patients from the same family with a heterozygous V186X mutation as the result of a 4-nucleotide insertion at the beginning of exon 5. Blood samples were drawn after informed consent was obtained from the patient or parents. The study was approved by the local institutional review board (CCPPRB 05632; Paris Saint Antoine) and was conducted in accordance with the Declaration of Helsinki.

- Revy P, et al. (2000) Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 102:565–575.
- Petersen-Mahrt SK, Harris RS, Neuberger MS (2002) AID mutates E. coli, suggesting a DNA deamination mechanism for antibody diversification. Nature 418:99–103.
- Muramatsu M, et al. (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA-editing enzyme. *Cell* 102:553–563.
- Imai K, et al. (2003) Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol 4: 1023–1028.
- Rada C, Di Noia JM, Neuberger MS (2004) Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. *Mol Cell* 16:163–171.
- Petersen S, et al. (2001) AID is required to initiate Nbs1/γ-H2AX focus formation and mutations at sites of class switching. Nature 414:660–665.
- 7. Guikema JE, et al. (2007) APE1- and APE2-dependent DNA breaks in immunoglobulin class switch recombination. J Exp Med 204:3017–3026.
- Manis JP, et al. (2004) 53BP1 links DNA damage-response pathways to immunoglobulin heavy chain class-switch recombination. Nat Immunol 5:481–487.
- Reina-San-Martin B, Chen HT, Nussenzweig A, Nussenzweig MC (2004) ATM is required for efficient recombination between immunoglobulin switch regions. J Exp Med 200:1103–1110.
- Celeste A, et al. (2002) Genomic instability in mice lacking histone H2AX. Science 296: 922–927.
- Kracker S, et al. (2005) Nibrin functions in Ig class-switch recombination. Proc Natl Acad Sci USA 102:1584–1589.
- Reina-San-Martin B, Nussenzweig MC, Nussenzweig A, Difilippantonio S (2005) Genomic instability, endoreduplication, and diminished Ig class-switch recombination in B cells lacking Nbs1. Proc Natl Acad Sci USA 102:1590–1595.
- Franco S, et al. (2006) H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell 21:201–214.
- Dinkelmann M, et al. (2009) Multiple functions of MRN in end-joining pathways during isotype class switching. Nat Struct Mol Biol 16:808–813.
- Yan CT, et al. (2007) IgH class switching and translocations use a robust nonclassical end-joining pathway. *Nature* 449:478–482.
- Boboila C, et al. (2010) Alternative end-joining catalyzes class switch recombination in the absence of both Ku70 and DNA ligase 4. J Exp Med 207:417–427.
- Pan-Hammarström Q, et al. (2005) Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J Exp Med 201: 189–194.
- Soulas-Sprauel P, et al. (2007) Role for DNA repair factor XRCC4 in immunoglobulin class switch recombination. J Exp Med 204:1717–1727.
- Corneo B, et al. (2007) Rag mutations reveal robust alternative end joining. Nature 449:483–486.
- Imai K, et al. (2005) Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2. *Clin Immunol* 115:277–285.
- Takizawa M, et al. (2008) AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J Exp Med 205:1949–1957.
- Sernández IV, de Yébenes VG, Dorsett Y, Ramiro AR (2008) Haploinsufficiency of activation-induced deaminase for antibody diversification and chromosome translocations both in vitro and in vivo. *PLoS ONE* 3:e3927.

Amplification and Analysis of Sµ–S α **Recombination Junctions.** Genomic DNA was purified from peripheral blood, and 30 ng of DNA was used as a template in each individual PCR. Amplification was performed as described previously (24), but using Go-Taq (Promega). Sµ–S α fragments were gel-purified (Roche), cloned into Topo-TA vector (Invitrogen), and sequenced with an automated fluorescent sequencer (MilleGen). CSRs were identified by aligning the S fragment sequences with Sµ (X54713), S α 1 (L19121), and S α 2 (AF030305). Microhomology was defined as successive nucleotides shared by Sµ and S α at the S junction, with no mismatches. A nucleotide at the breakpoints that was not identical to either of the S regions was defined as an insertion. Polymorphisms in the S region were excluded from the mutation analysis.

ACKNOWLEDGMENTS. We thank M. Forveille for excellent technical assistance. This work was funded by grants from Institut National de la Santé et de la Recherche Médicale, European Union Framework Programme 7 EUROPAD (Primary Antibody Deficiencies) Contract 201549, and Association Contre Le Cancer.

- Robbiani DF, et al. (2009) AID produces DNA double-strand breaks in non-lg genes and mature B cell lymphomas with reciprocal chromosome translocations. *Mol Cell* 36:631–641.
- Pan Q, et al. (2002) Alternative end joining during switch recombination in patients with ataxia-telangiectasia. Eur J Immunol 32:1300–1308.
- He B, et al. (2007) Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial cell secretion of the cytokine APRIL. *Immunity* 26:812–826.
- Fagarasan S, Kinoshita K, Muramatsu M, Ikuta K, Honjo T (2001) In situ class switching and differentiation to IgA-producing cells in the gut lamina propria. *Nature* 413: 639–643.
- Du L, et al. (2008) Involvement of Artemis in nonhomologous end-joining during immunoglobulin class switch recombination. J Exp Med 205:3031–3040.
- Schrader CE, et al. (2003) Mutations occur in the Ig Smu region but rarely in Sgamma regions prior to class switch recombination. *EMBO J* 22:5893–5903.
- Nagaoka H, Muramatsu M, Yamamura N, Kinoshita K, Honjo T (2002) Activationinduced deaminase (AID)-directed hypermutation in the immunoglobulin Smu region: Implication of AID involvement in a common step of class switch recombination and somatic hypermutation. J Exp Med 195:529–534.
- Faili A, et al. (2004) DNA polymerase eta is involved in hypermutation occurring during immunoglobulin class switch recombination. J Exp Med 199:265–270.
- Péron S, et al. (2008) Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med 205:2465–2472.
- Barreto V, Reina-San-Martin B, Ramiro AR, McBride KM, Nussenzweig MC (2003) C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. *Mol Cell* 12:501–508.
- Geisberger R, Rada C, Neuberger MS (2009) The stability of AID and its function in class-switching are critically sensitive to the identity of its nuclear-export sequence. *Proc Natl Acad Sci USA* 106:6736–6741.
- 34. Gu J, et al. (2007) XRCC4:DNA ligase IV can ligate incompatible DNA ends and can ligate across gaps. *EMBO J* 26:1010–1023.
- Schenten D, et al. (2009) Pol zeta ablation in B cells impairs the germinal center reaction, class switch recombination, DNA break repair, and genome stability. J Exp Med 206:477–490.
- Lieber MR, Wilson TE (2010) SnapShot: Nonhomologous DNA end-joining (NHEJ). Cell 142:496.
- Bothmer A, et al. (2010) 53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination. J Exp Med 207: 855–865.
- Roberts SA, et al. (2010) Ku is a 5'-dRP/AP lyase that excises nucleotide damage near broken ends. Nature 464:1214–1217.
- Ta VT, et al. (2003) AID mutant analyses indicate requirement for class-switch specific cofactors. Nat Immunol 4:843–848.
- Begum NA, et al. (2009) Further evidence for involvement of a noncanonical function of uracil DNA glycosylase in class switch recombination. Proc Natl Acad Sci USA 106: 2752–2757.
- Schrader CE, Vardo J, Stavnezer J (2002) Role for mismatch repair proteins Msh2, Mlh1, and Pms2 in immunoglobulin class switching shown by sequence analysis of recombination junctions. J Exp Med 195:367–373.
- van Oers JM, et al. (2010) PMS2 endonuclease activity has distinct biological functions and is essential for genome maintenance. Proc Natl Acad Sci USA 107:13384–13389.
- Lieber MR (2010) NHEJ and its backup pathways in chromosomal translocations. Nat Struct Mol Biol 17:393–395.